Characteristics of dermatomyositis patients with and without associated malignancy.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
03
11
2020
accepted:
07
05
2021
pubmed:
6
11
2021
medline:
15
12
2021
entrez:
5
11
2021
Statut:
ppublish
Résumé
Dermatomyositis belongs to the rare idiopathic, inflammatory myositis group. A previously postulated link between some cases of dermatomyositis and malignancy has been established in recent years. Criteria suggestive of a malignancy association are still being explored. We retrospectively analyzed data from 63 patients with dermatomyositis over a period of 15 years. The following criteria argue for cancer-associated dermatomyositis: older age (> 52 years [P = 0.001], > 65 years [P = 0.002], ≥ 75 years [P = 0.002]), shorter time between manifestation and diagnosis of dermatomyositis (malignancy group: 59 days vs. non-malignancy group: 137 days [P = 0.022]), typical skin involvement such as Gottron sign (P = 0.045), centrofacial erythema (P = 0.036) and typical erythema on the upper arms and forearms (P = 0.019), oropharyngeal involvement (P = 0.015) and increased ALT (P = 0.031). The following criteria argue for non-cancer-associated dermatomyositis: younger age (≤ 52 years [P = 0.001], 40-65 years [P = 0.045]) and pruritus (P = 0.026). The aforementioned criteria have been documented in the literature, but reported findings are heterogenous concerning the suitability of their markers for malignancy association. Small study populations, few prospective controlled studies, summarization of different forms of myositis and inconsistent use nomenclature contribute to biased results. Our study aims to make an important contribution toward the identification of risk factors in cancer-associated dermatomyositis.
Sections du résumé
BACKGROUND
Dermatomyositis belongs to the rare idiopathic, inflammatory myositis group. A previously postulated link between some cases of dermatomyositis and malignancy has been established in recent years. Criteria suggestive of a malignancy association are still being explored.
PATIENTS AND METHODS
We retrospectively analyzed data from 63 patients with dermatomyositis over a period of 15 years.
RESULTS
The following criteria argue for cancer-associated dermatomyositis: older age (> 52 years [P = 0.001], > 65 years [P = 0.002], ≥ 75 years [P = 0.002]), shorter time between manifestation and diagnosis of dermatomyositis (malignancy group: 59 days vs. non-malignancy group: 137 days [P = 0.022]), typical skin involvement such as Gottron sign (P = 0.045), centrofacial erythema (P = 0.036) and typical erythema on the upper arms and forearms (P = 0.019), oropharyngeal involvement (P = 0.015) and increased ALT (P = 0.031). The following criteria argue for non-cancer-associated dermatomyositis: younger age (≤ 52 years [P = 0.001], 40-65 years [P = 0.045]) and pruritus (P = 0.026).
CONCLUSIONS
The aforementioned criteria have been documented in the literature, but reported findings are heterogenous concerning the suitability of their markers for malignancy association. Small study populations, few prospective controlled studies, summarization of different forms of myositis and inconsistent use nomenclature contribute to biased results. Our study aims to make an important contribution toward the identification of risk factors in cancer-associated dermatomyositis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1601-1611Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Volc-Platzer B. Dermatomyositis-update. Hautarzt 2015; 66: 604-10.
Andras C, Ponyi A, Constantin T et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35: 438-44.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
Didona D, Juratli HA, Scarsella L et al. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol 2020; 30: 229-42.
Fardet L, Dupuy A, Gain M et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-7.
Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006; 24: 363-73.
Schlecht N, Sunderkötter C, Niehaus S, Nashan D. Update on dermatomyositis in adults. J Dtsch Dermatol Ges 2020; 18: 995-1013.
Sunderkötter C, Nast A, Worm M et al. Guidelines on dermatomyositis - excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges 2016; 14: 321-38.
Andras C, Bodoki L, Nagy-Vincze M et al. Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort. Pathol Oncol Res 2020; 26: 1749-55.
Liakou AI, Trebing D, Zouboulis CC. Paraneoplastic dermatomyositis associated with metastatic melanoma. J Dtsch Dermatol Ges 2012; 10: 63-4.
Scerri L, Zaki I, Allen BR, Golding P. Dermatomyositis associated with malignant melanoma - case report and review of the literature. Clin Exp Dermatol 1994; 19: 523-5.
Almodovar R, Lindo DP, Martin H et al. Dermatomyositis and meningioma in the same patient. Reumatol Clin 2012; 8: 87-9.
Sonnenblick A. Carcinoma of unknown primary and paraneoplastic dermatomyositis. World J Clin Oncol 2015; 6: 295-8.
Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-15.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-7.
Lu X, Yang H, Shu X et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9: e94128.
Fang YF, Wu YJ, Kuo CF et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol 2016; 35: 1977-84.
Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med 2018; 41: 103-12.
Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387-408.
Anyanwu CO, Fiorentino DF, Chung L et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 2015; 173: 969-74.
Lundberg IE, Tjarnlund A, Bottai M et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955-64.
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51: 638-56.
Didona D, Juratli HA, Scarsella L et al. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria. Eur J Dermatol 2020; 30: 279-88.
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85: 41-5.
Tang MM, Thevarajah S. Paraneoplastic dermatomyositis: a 12-year retrospective review in the department of dermatology hospital Kuala Lumpur. Med J Malaysia 2010; 65: 138-42.
Marie I, Hatron PY, Levesque H et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78: 139-47.
Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
Lauinger J, Volc S, Ghoreschi K. Bullous skin lesions in a 65-year-old man. J Dtsch Dermatol Ges 2020; 18: 266-9.
Tu J, Von Nida J. Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon. Australas J Dermatol 2011; 52: e7-10.
Maoz CR, Langevitz P, Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998; 27: 319-24.
Gluck Z, Kutsherowsky M, Abraham Z, Galper I. Dermatomyositis, carcinoma of colon and meningioma in the same patient. J Dermatol 1993; 20: 719-22.
Buchbinder R, Forbes A, Hall S et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 2017; 21: 131-6.
Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144: 825-31.
Gallais V, Crickx B, Belaich S. [Prognostic factors and predictive signs of malignancy in adult dermatomyositis]. Ann Dermatol Venereol 1996; 123: 722-6.
Kim HJ, Zeidi M, Bonciani D et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol 2018; 179: 669-78.
So MW, Koo BS, Kim YG et al. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 2011; 38: 2432-5.
Prohic A, Kasumagic-Halilovic E, Simic D, Selmanagic A. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009; 23: 591-2.
Lee SW, Jung SY, Park MC et al. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 2006; 47: 519-23.
Nicoletis I, Pasco J, Maillot F et al. High pre-treatment neutrophil-to-lymphocyte ratio in patients with dermatomyositis/polymyositis predicts an increased risk of cancer. Eur J Dermatol 2020 Apr 10 [Epub ahead of print].
Maier L, Betteridge Z, Udvardi A et al. Paraneoplastic dermatomyositis: relevance of myositis-specific autoantibodies in a small cohort. J Eur Acad Dermatol Venereol 2020; 34: e50-1.